A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Background: To define the best timing for the treatment of high maternal viral DNA levels in order to block the mother-to-child transmission (MTCT).Methods: From a total of 820 HBsAg-positive pregnant women, 229 who satisfied the selection criteria were enrolled for the final analysis. These patients were divided into thress groups: Group A: 62 patients received telbivudine (LdT) (600 mg/day, orally) treatment before pregnant; Group B: 101 patients received LdT treatment at 24-28 weeks ofdoi:10.21203/rs.3.rs-550967/v1 fatcat:xwwsjsan5rampjx3y72s4mdvyq